Celgene to Acquire Pharmion for $2.9 Billion in Cash and Stock Celgene Company and Pharmion Corporation jointly announced the signing of a definitive merger contract pursuant to which Celgene has agreed to acquire Pharmion. Under the conditions of the merger contract, Celgene will acquire all of the exceptional shares of Pharmion common stock for $72.00 per share payable in a combination of shares and cash of Celgene common stock. The transaction is expected to be somewhat dilutive to revenue in 2008 and accretive in 2009 2009 and beyond. The acquisition of Pharmion furthers Celgene’s technique to become a global innovator in the hematology/oncology field. The transaction includes three meaningful therapies medically, Revlimid, Thalomid and Vidaza, dealing with different patient populations worldwide.Dr Christopher P. Crum, Director of Women’s and Perinatal Pathology in the Section of pathology at BWH, said, ‘It has been a decades-older mystery why cervical cancers caused by HPV arise only from a discrete region of the cervix, known as the ‘squamocolumnar junction’, despite the presence of the virus throughout the genital system. The discovery of the cells finally resolves this mystery and can have wide-ranging impact from developing more meaningful animal models of early cervical carcinogenesis to clinical implications.’ The team found that this discrete set of cells, located at the squamocolumnar junction of the cervix, uniquely express biomarkers that are seen in all types of invasive cervical cancers associated with HPV.